Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 9/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | GPR52 | Q9Y2T5 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.41 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22604451 | 0.89 | CAMK2D (0.48) | FYNMAP4K4PRKD1 | |
| SCHEMBL22604315 | 0.86 | SRC (0.65) | FYNSRCGPR52MAPTLMNA | |
| SCHEMBL20898225 | 0.85 | SRC (0.50) | SRCMAPTLMNAKMT2AGAA | |
| SCHEMBL30662364 | 0.85 | SRC (0.50) | SRCMAPTLMNAKMT2AGAA | |
| SCHEMBL20911860 | 0.84 | SRC (0.49) | FYNSRCMAPTLMNAKMT2A | |
| SCHEMBL8819526 | 0.81 | SRC (0.64) | SRCMAPTLMNAKMT2AGAA | |
| SCHEMBL20912011 | 0.81 | SRC (0.51) | FYNSRCMAPTLMNAKMT2A | |
| SCHEMBL20911641 | 0.81 | SRC (0.48) | SRCMAPTLMNAKMT2AGAA | |
| SCHEMBL20911969 | 0.80 | MAPT (0.46) | SRCMAPTLMNAKMT2AHTT | |
| SCHEMBL20898188 | 0.79 | SRC (0.43) | SRCMAPTLMNAKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795169-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-11795169-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-20200339583-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339583-A1 | MAP4K4 INHIBITORS | MAP4K4, MAP4K2, MAP4K5 | FYN 306/4885SRC 594/4885GPR52 2649/4885 |
| US-11795169-B2 | MAP4K4 inhibitors | MAP4K4, MAP4K2, MAP4K5 | FYN 306/4885SRC 594/4885GPR52 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.